Novo Nordisk (CPSE:NOVO B) Set To Unveil New Obesity Data At ObesityWeek 2026

What happened: Novo Nordisk (CPSE:NOVO B) plans to unveil new obesity portfolio data at ObesityWeek 2026 in early November, including real-world Wegovy findings and investigational CagriSema results. Key numbers: Market cap DKK1.2 trillion. Fair value cited at DKK298. Event in early November 2026. Why it matters: The data will shape how payers, regulators and prescribers compare Novo Nordisk's portfolio with Eli Lilly's GLP-1 and oral competitors, though it does not address future pricing pressure. Market: +1.1% today ($40.45), -20.0% YTD, 1.1x vol — as of 23:46 UTC

Novo Nordisk (CPSE:NOVO B) plans to unveil new obesity portfolio data at ObesityWeek 2026 in early November, including real-world Wegovy findings and investigational CagriSema results.

The data will shape how payers, regulators and prescribers compare Novo Nordisk's portfolio with Eli Lilly's GLP-1 and oral competitors, though it does not address future pricing pressure. Market: +1.1% today ($40.45), -20.0% YTD, 1.1x vol — as of 23:46 UTC